What Has Driven the Growth of the Rare Neurological Disease Treatment Market in Recent Years?
The rare neurological disease treatment market has seen considerable growth due to a variety of factors.
•The market for treatment of uncommon neurological disorders has seen pronounced growth over the past years. It is projected to expand from $9.85 billion in 2024 to $10.68 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.4%.
Contributing factors to this growth in the past include the introduction of biosimilars in treating rare diseases, the global expansion of clinical trials, healthcare repayment policies, orphan drug designations as well as advancements in genetically oriented research.
What is the Market Size Forecast for the Rare Neurological Disease Treatment Market?
The rare neurological disease treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for the treatment of rare neurological diseases is anticipated to witness substantial growth in the upcoming years, reaching $14.84 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%.
This growth during the forecast period can be attributed to enhancements in diagnostic tools, advancements in precision medicine, development of drugs that are centered around the patient, incorporation of real-world evidence, use of telemedicine for patient assistance, and a shift towards personalized therapies. During the forecast period, major trends will encompass technological innovations, the application of artificial intelligence in drug discovery, the utilization of blockchain for securing data, and the use of machine learning in drug discovery.
What Are The Core Factors Supporting Growth In The Rare Neurological Disease Treatment Market?
The increase in rare neurological conditions is predicted to catalyze the expansion of the rare neurological disease treatment market. These uncommon neurological disorders, which include Huntington's disease, ALS (amyotrophic lateral sclerosis), Rett syndrome, and multiple forms of muscular dystrophy, are known for their low frequency. The treatment of these rare neurological diseases involves varied strategies to manage symptoms, delay the disease's advancement, and enhance the life quality of those impacted by such conditions. For example, BioMed Central Ltd., a British publisher of open-access scientific periodicals, reported in an article published in January 2023, that there was a combined prevalence of Rett syndrome, amounting to 7.1 per 100,000 females in a cumulative sample of 9.57 million women, with a total 673 confirmed cases. As such, the occurrence of these rare neurological diseases is significantly contributing to the growth of the rare neurological disease treatment market.
What Are The Major Segments Within The Global Rare Neurological Disease Treatment Market?
The rare neurological disease treatment market covered in this report is segmented –
1) By Drug Type: Biologics, Small Molecules
2) By Therapy: Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies
3) By Mode Of Administration: Oral, Injectable, Other Modes Of Administration
4) By Disorders: Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies
Subsegments:
1) By Biologics: Monoclonal Antibodies, Gene Therapies, Recombinant Proteins
2) By Small Molecules: Targeted Small Molecules, Neuroprotective Agents, Anti-inflammatory Small Molecules
Pre-Book The Rare Neurological Disease Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Rare Neurological Disease Treatment Market?
One trend that is seeing a surge of uptake in the rare neurological disease treatment market is the advancement of orphan drugs. Companies in this sector are primarily concentrating their efforts on the creation of unique, cutting-edge treatments to solidify their market standing. For example, Orphalan SA, a company in France that develops orphan drugs, launched a trailblazing tetrahydrochloride product, Cuvrior, into the European market in April 2023. Cuvrior, which is specifically designed for adult patients suffering from stable Wilson disease who have responded well to copper reduction therapy and tolerate D-penicillamine, is currently commercially available. The United States Food and Drug Administration (FDA) gave the green light for their product and granted it Orphan Drug Exclusivity (ODE) in April 2022, specifically for treating this group of patients.
Who Are the Key Players in the Rare Neurological Disease Treatment Market?
Major companies operating in the rare neurological disease treatment market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi-Aventis SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Medtronic PLC
• Teva Pharmaceutical Industries Ltd.
• CSL Limited
• Biogen Inc.
• UCB S.A.
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Jazz Pharmaceuticals PLC
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences Inc.
• Kedrion Biopharma Inc.
• Merz Pharma GmbH & Co. KGaA
• Harmony Biosciences Holdings Inc.
• Amicus Therapeutics Inc.
• Revance Therapeutics Inc.
• Aquestive Therapeutics Inc.
• US WorldMeds LLC (Solstice Neurosciences LLC)
• Stoke Therapeutics Inc.
• Retrotope Inc.
What Is The Most Dominant Region In The Rare Neurological Disease Treatment Market?
North America was the largest region in the rare neurological diseases treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
